Business
Update to Admission of Fundraising Shares
Cellbxhealth plc has provided an update on the admission of its fundraising shares, with First Admission of 9,090,000 First Tranche Fundraising Shares expected around December 16, 2025, and Second Admission for up to 770,910,000 Second Tranche Placing Shares, Subscription Shares, and Retail Offer Shares anticipated on December 18, 2025, subject to resolutions being passed. Disclaimer*
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\nCELLBXHEALTH plc\n(\"CELLBXHEALTH\", the \"Company\" or the \"Group\")\nUpdate to Admission of Fundraising Shares\nCELLBXHEALTH plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence announces, following the conclusion of the oversubscribed Placing, the following update with regards Admission of the Fundraising Shares.\nSubject to the passing of the Resolutions, First Admission will be in respect of 9,090,000 First Tranche Fundraising Shares and is expected to occur at 8.00 a.m. on or around 16 December 2025. Second Admission will be in respect of up to 770,910,000 Second Tranche Placing Shares, the Subscription Shares and the Retail Offer Shares and is expected to occur at 8.00 a.m. on 18 December 2025 (or, in each case, such later time and/or date as Cavendish and the Company and Cavendish may agree, not (being no later than 8.00 a.m. on 16 January 2026).\nCapitalised terms used but not defined in this announcement have the meanings given to them in the Launch Announcement, unless context provides otherwise.\nFor further information:\n \n\n\n\n\nCelLBxHealth plc\n\n\n+44 (0) 1483 343434\n\n\n\n\nPeter Collins, Chief Executive Officer\n\n\n [email protected]\n \n\n\n\n\nCavendish (NOMAD and Broker)\nGeoff Nash / Isaac Hooper / Hamza Munshi (Corporate Finance)\nSunila de Silva (Corporate Broking)\nNigel Birks (Life Science Specialist Sales)\n\n\n \n+44 (0) 20 7220 0500\n\n\n\n\n \nFTI Consulting\nSimon Conway, Ciara Martin, Sam Purewal\n \n\n\n \n \n+44 (0) 203 727 1000\n\n\n\n\nThis Announcement is for information purposes only and does not constitute an offer to sell or issue or the solicitation of an offer to buy, acquire or subscribe for shares in the capital of the Company in the United States, Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction where such offer or solicitation may be restricted, unlawful or unauthorised. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. Subject to certain exemptions, the securities referred to herein may not be offered or sold in Canada, Australia, Japan or the Republic of South Africa or to, or for the account or benefit of any national resident or citizen of Canada, Australia, Japan or the Republic of Sou...